Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study

por McDonnell, David P., Landry, John, Detke, Holland C.
Publicado 2014

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment

por Detke, Holland C., Lauriello, John, Landry, John, McDonnell, David P.
Publicado 2014

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendat...

por Anand, Ernie, Berggren, Lovisa, Deix, Claudia, Tóth, Ágoston, McDonnell, David P
Publicado 2015

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

por Atkins, Susan, Detke, Holland C, McDonnell, David P, Case, Michael G, Wang, Shufang
Publicado 2014

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

por Hill, Angela L, Sun, Bin, Karagianis, Jamie L, Watson, Susan B, McDonnell, David P
Publicado 2011

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, explorator...

por Ascher-Svanum, Haya, Montgomery, William S, McDonnell, David P, Coleman, Kristina A, Feldman, Peter D
Publicado 2012

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

por Detke, Holland C, McDonnell, David P, Brunner, Elizabeth, Zhao, Fangyi, Sorsaburu, Sebastian, Stefaniak, Victoria J, Corya, Sara A
Publicado 2010

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

por Katagiri, Hideaki, Tohen, Mauricio, McDonnell, David P, Fujikoshi, Shinji, Case, Michael, Kanba, Shigenobu, Takahashi, Michihiro, Gomez, Juan-Carlos
Publicado 2013

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective...

por Jones, Meghan E., Andrews, Jeffrey S., Faries, Douglas E., Landry, John, Xu, Jenny, Detke, Holland C., Chhabra-Khanna, Rashna, McDonnell, David P.
Publicado 2015

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

por McDonnell, David P, Detke, Holland C, Bergstrom, Richard F, Kothare, Prajakti, Johnson, Jason, Stickelmeyer, Mary, Sanchez-Felix, Manuel V, Sorsaburu, Sebastian, Mitchell, Malcolm I
Publicado 2010

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

por Ascher-Svanum, Haya, Zhao, Fangyi, Detke, Holland C, Nyhuis, Allen W, Lawson, Anthony H, Stauffer, Virginia L, Montgomery, William, Witte, Michael M, McDonnell, David P
Publicado 2011